December 31, 2020
Tag: Clinical Immunotherapy Program
September 9, 2020
Immuno-Oncology News: Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial
August 6, 2020
Targeted Oncology: Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma
August 6, 2020
OncLive: CD30-Targeted CAR T-Cell Therapy Elicits Durable Responses in Relapsed/Refractory Hodgkin Lymphoma
August 5, 2020
HemOnc Today: Anti-CD30 CAR T-cell therapy appears safe, effective in advanced Hodgkin lymphoma
July 23, 2020
Excellent research results for CAR-T therapy against Hodgkin lymphoma
CAR-T immunotherapy has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
March 11, 2020
Triangle Business Journal: UNC researchers highlight breakthrough for Hodgkin’s lymphoma treatment
February 13, 2020
CAR-T therapy gives patient options after cancer returns
When traditional cancer treatment options failed, Sabrina Shelton's care team referred her to UNC for a CAR-T therapy clinical trial.
January 30, 2020
UNC Lineberger discovery would allow researchers to fine-tune activity of cancer-hunting immune cells
A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects. In a study published in Cancer Cell, researchers led by UNC Lineberger’s Gianpietro Dotti, …
May 20, 2019
UNC Lineberger designs, develops and delivers CAR-T therapy to attack cancers
Jonathan Serody, MD, explains in a two-minute video the action behind chimeric antigen T-cell, or CAR-T, immunotherapy and how UNC Lineberger is designing, developing and delivering CAR-T therapies to treat cancers that fail to respond to standard treatments.